Ovarian cancer evolution through stochastic genome alterations: Defining the genomic role in ovarian cancer

Systems Biology in Reproductive Medicine

Volumn 60, Issue 1, 2014, Pages 2-13

  Abdallah, Batoul Y ^a   Horne, Steven D ^a   Kurkinen, Markku ^a   Stevens, Joshua B ^a   Liu, Guo ^a   Ye, Christine J ^a   Barbat, Justin ^a   Bremer, Steven W ^a   Heng, Henry H Q ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clonal chromosomal aberration; Evolutionary mechanism of cancer; Genome chaos; Genome replacement; Genome theory; Nonclonal chromosomal aberration; Ovarian cancer; Two phases of cancer evolution

Indexed keywords

CELL IMMORTALIZATION; CELL POPULATION; CELL TRANSFORMATION; CLINICAL RESEARCH; EVOLUTION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOMICS; HUMAN; HUMAN GENOME; MOUSE MODEL; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; FEMALE; GENE EXPRESSION PROFILING; GENOME; HUMANS; MICE; OVARIAN NEOPLASMS; STOCHASTIC PROCESSES;

EID: 84892705757     PISSN: 19396368     EISSN: 19396376     Source Type: Journal    
DOI: 10.3109/19396368.2013.837989     Document Type: Review

References (132)

1. Baca, S.C., Prandi, D., Lawrence, M.S., Mosquera, J.M., Romanel, A., Drier, Y., et al. (2013) Punctuated evolution of prostate cancer genomes. Cell 153: 666-677.
2. Bast, Jr., R.C., Hennessy, B., and Mills, G.B. (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428.
3. Bast, Jr., R.C., Xu, F.J., Yu, Y.H., Barnhill, S., Zhang, Z., and Mills, G.B. (1998) CA 125: the past and the future. Int J Biol Markers 13: 179-187.
4. Bayani, J., Brenton, J.D., Macgregor, P.F., Beheshti, B., Albert, M., Nallainathan, D., et al. (2002) Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res 62: 3466-3476.
5. Bayani, J., Paderova, J., Murphy, J., Rosen, B., Zielenska, M., and Squire, J.A. (2008) Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer. Neoplasia 10: 1057-1065.
6. Birrer, M.J. (2010) The origin of ovarian cancer-is it getting clearer? N Engl J Med 363: 1574-1575.
7. Bonome, T., Levine, D.A., Shih, J., Randonovich, M., Pise-Masison, C.A., Bogomolniy, F., et al. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68: 5478-5486.
8. Brown, P.O., and Palmer, C. (2009) The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 6:e1000114.
9. Burger, R.A., Brady, M.F., Bookman, M.A., Fleming, G.F., Monk, B.J., Huang, H., et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-2483.
10. Capp, J.P. (2005) Stochastic gene expression, disruption of tissue averaging effects and cancer as a disease of development. Bioessays 27: 1277-1285.
11. Castro, M.A., Onsten, T.T., de Almeida, R.M., and Moreira, J.C. (2005) Profiling cytogenetic diversity with entropy-based karyotypic analysis. J Theor Biol 234: 487-495.
12. Chan, J., Fuh, K., Shin, J., Cheung, M., Powell, C., Chen, L.M., et al. (2008) The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? Br J Cancer 98: 1191-1196.
13. Chuaire-Noack, L., Rondon-Lagos, S., Ramirez-Corredor, A., Ibanez-Pinilla, M., and Ramirez-Clavijo, S. (2010) Cytogenetic aberrations in primary cell cultures of the ovarian surface epithelium. Invest Clin 51: 541-551.
14. Clark-Knowles, K.V., Senterman, M.K., Collins, O., and Vanderhyden, B.C. (2009) Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One 4: e8534.
15. Cohn, D.E., Valmadre, S., Resnick, K.E., Eaton, L.A., Copeland, L.J., and Fowler, J.M. (2006) Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 102: 134-139.
16. Collins, F.S., and Barker, A.D. (2007) Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am 296: 50-57.
17. Cooke, S.L., Ng, C.K., Melnyk, N., Garcia, M.J., Hardcastle, T., Temple, J., et al. (2010) Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 29: 4905-4913.
18. Creekmore, A.L., Silkworth, W.T., Cimini, D., Jensen, R.V., Roberts, P.C., and Schmelz, E.M. (2011) Changes in gene expression and cellular architecture in an ovarian cancer progression model. PLoS One 6:e17676.
19. Ding, L., Ellis, M.J., Li, S., Larson, D.E., Chen, K., Wallis, J.W., et al. (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999-1005.
20. du Bois, A., Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., et al. (2006) Addition of epirubicin as a third drug to carboplatinpaclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24: 1127-1135.
21. Dubeau, L. (2008) The cell of origin of ovarian epithelial tumours. Lancet Oncol 9: 1191-1197.
22. Duesberg, P., Li, R., Sachs, R., Fabarius, A., Upender, M.B., and Hehlmann, R. (2007) Cancer drug resistance: the central role of the karyotype. Drug Resist Updat 10: 51-58.
23. Ercan, S., Kaymaz, O., Yucel, N., and Orcun, A. (2012) Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study. Arch Gynecol Obstet 285: 579-584.
24. Fearon, E.R., and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
25. Gerlinger, M., and Swanton, C. (2010) How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 103: 1139-1143.
26. Gevaert, O., De Smet, F., Van Gorp, T., Pochet, N., Engelen, K., Amant, F., et al. (2008) Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation. BMC Cancer 8:18.
27. Gillies, R.J., Verduzco, D., and Gatenby, R.A. (2012) Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 12: 487-493.
28. Gorelick, R., and Heng, H.H. (2010) Sex reduces genetic variation: a mltidisciplinary review. Evolution 65: 1088-1098.
29. Gregoire, L., Rabah, R., Schmelz, E.M., Munkarah, A., Roberts, P.C., and Lancaster, W.D. (2001) Spontaneous malignant transformation of human ovarian surface epithelial cells in vitro. Clin Cancer Res 7: 4280-4287.
30. Hanahan, D., and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
31. Harewood, L., Schutz, F., Boyle, S., Perry, P., Delorenzi, M., Bickmore, W.A., et al. (2010) The effect of translocation-induced nuclear reorganization on gene expression. Genome Res 20: 554-564.
32. Heng, H.H. (2000) Released chromatin or DNA fiber preparations for high-resolution fiber FISH. Methods Mol Biol 123: 69-81.
33. Heng, H.H., Bremer, S.W., Stevens, J., Ye, K.J., Miller, F., Liu, G., et al. (2006a) Cancer progression by non-clonal chromosome aberrations. J Cell Biochem 98: 1424-1435.
34. Heng, H.H., Liu, G., Bremer, S., Ye, K.J., Stevens, J., and Ye, C.J. (2006b) Clonal and non-clonal chromosome aberrations and genome variation and aberration. Genome 49: 195-204.
35. Heng, H.H., Stevens, J.B., Liu, G., Bremer, S.W., Ye, K.J., Reddy, P.V., et al. (2006c) Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol 208: 461-472.
36. Heng, H.H. (2007a) Cancer genome sequencing: the challenges ahead. Bioessays 29: 783-794.
37. Heng, H.H. (2007b) Elimination of altered karyotypes by sexual reproduction preserves species identity. Genome 50: 517-524.
38. Heng, H.H. (2007c) Karyotypic chaos, a form of non-clonal chromosome aberrations, plays a key role for cancer progression and drug resistance. FASEB Meeting: Nuclear Structure and Cancer, Vermont Academy, Saxtons River, Vermont, June 16-21.
39. Heng, H.H. (2008a) The conflict between complex systems and reductionism. JAMA 300: 1580-1581.
40. Heng, H.H. (2008b) The gene-centric concept: a new liability? Bioessays 30: 196-197.
41. Heng, H.H., Stevens, J.B., Lawrenson, L., Liu, G., Ye, K.J., Bremer, S.W., et al. (2008) Patterns of genome dynamics and cancer evolution. Cell Oncol 30: 513-514.
42. Heng, H.H. (2009) The genome-centric concept: resynthesis of evolutionary theory. Bioessays 31: 512-525.
43. Heng, H.H. (2010) Missing heritability and stochastic genome alterations. Nat Rev Genet 11:813.
44. Heng, H.H., Liu, G., Stevens, J.B., Bremer, S.W., Ye, K.J., and Ye, C.J. (2010a) Genetic and epigenetic heterogeneity in cancer: the ultimate challenge for drug therapy. Curr Drug Targets 11: 1304-1316.
45. Heng, H.H., Stevens, J.B., Bremer, S.W., Ye, K.J., Liu, G., and Ye, C.J. (2010b) The evolutionary mechanism of cancer. J Cell Biochem 109: 1072-1084.
46. Heng, H.H., Liu, G., Stevens, J.B., Bremer, S.W., Ye, K.J., Abdallah, B.Y., et al. (2011a) Decoding the genome beyond sequencing: the new phase of genomic research. Genomics 98: 242-252.
47. Heng, H.H., Stevens, J.B., Bremer, S.W., Liu, G., Abdallah, B.Y., and Ye, C.J. (2011b) Evolutionary mechanisms and diversity in cancer. Adv Cancer Res 112: 217-253.
48. Heng, H.H. (2013) Biocomplexity: challenging reductionism. In: Handbook on Systems and Complexity in Health. Sturmberg JP, Martin CM, eds. New York: Springer, pp. 193-208.
49. Heng, H.H., Liu, G, Stevens, J.B., Abdallah, B.Y., Horne, S.D., Ye, K.J., et al. (2013a) Karyotype heterogeneity and unclassified chromosomal abnormalities. Cytogenet Genome Res 139: 144-157.
50. Heng, H.H., Bremer, S.W., Stevens, J.B., Horne, S.D., Liu, G., Abdallah, B.Y., et al. (2013b) Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution. Cancer Metastasis Rev, in press.
51. Hoglund, M., Gisselsson, D., Hansen, G.B., Sall, T., and Mitelman, F. (2003) Ovarian carcinoma develops through multiple modes of chromosomal evolution. Cancer Res 63: 3378-3385.
52. Hoglund, M., Frigyesi, A., Sall, T., Gisselsson, D., and Mitelman, F. (2005) Statistical behavior of complex cancer karyotypes. Genes Chromosomes Cancer 42: 327-341.
53. Horne, S.D., Stevens, J.B., Abdallah, B.Y., Liu, G., Bremer, S.W., Ye, C.J., et al. (2013a) Why imatinib remains an exception of cancer research. J Cell Physiol 228: 665-670.
54. Horne, S.D., Abdallah, B.Y., Stevens, J.B., Liu, G, Ye, K.J., Bremer, S.W., et al. (2013b) Genome constraint through sexual reproduction: application of 4D-Genomics in reproductive biology. Syst Biol Reprod Med 59: 124-130.
55. Hough, C.D., Sherman-Baust, C.A., Pizer, E.S., Montz, F.J., Im, D.D., Rosenshein, N.B., et al. (2000) Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60: 6281-6287.
56. Huang, S. (2012) Tumor progression: Chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution. Prog Biophys Mol Biol 110: 69-86.
57. Jacob, F., Meier, M., Caduff, R., Goldstein, D., Pochechueva, T., Hacker, N., et al. (2011) No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 121: 487-491.
58. Jazaeri, A.A., Yee, C.J., Sotiriou, C., Brantley, K.R., Boyd, J., and Liu, E.T. (2002) Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 94: 990-1000.
59. Jensen, R.B., Carreira, A., and Kowalczykowski, S.C. (2010) Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467: 678-683.
60. Jin, Y., Zhang, H., Tsao, S.W., Jin, C., Lv, M., Strombeck, B., et al. (2004) Cytogenetic and molecular genetic characterization of immortalized human ovarian surface epithelial cell lines: consistent loss of chromosome 13 and amplification of chromosome 20. Gynecol Oncol 92: 183-191.
61. Jorgensen, C., and Linding, R. (2010) Simplistic pathways or complex networks? Curr Opin Genet Dev 20: 15-22.
62. Kafali, H., Artuc, H., and Demir, N. (2004) Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary report. Eur J Obstet Gynecol Reprod Biol 116: 85-88.
63. Kaiser, J. (2012) Profile: Bert Vogelstein. Cancer genetics with an edge. Science 337: 282-284.
64. Kaye, S.B., Lubinski, J., Matulonis, U., Ang, J.E., Gourley, C., Karlan, B.Y., et al. (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30: 372-379.
65. Khalique, L., Ayhan, A., Weale, M.E., Jacobs, I.J., Ramus, S.J., and Gayther, S.A. (2007) Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol 211: 286-295.
66. Kiechle-Schwarz, M., Bauknecht, T., Schmidt, J., Walz, L., and Pfleiderer, A. (1995) Recurrent cytogenetic aberrations in human ovarian carcinomas. Cancer Detect Prev 19: 234-243.
67. Kobel, M., Kalloger, S.E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., et al. (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5:e232.
68. Konstantinopoulos, P.A., Spentzos, D., and Cannistra, S.A. (2008) Geneexpression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 5: 577-587.
69. Kreso, A., O'Brien, C.A., van Galen, P., Gan, O.I., Notta, F., Brown, A.M., et al. (2013) Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339: 543-548.
70. Kuczek, T., and Axelrod, D.E. (1987) Tumor cell heterogeneity: dividedcolony assay for measuring drug response. Proc Natl Acad Sci USA 84: 4490-4494.
71. Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214.
72. Lawrenson, L. (2010) Tracking profiles of genomic instability in spontaneous transformation and tumorigenesis. Wayne State University Press, Wayne State University, Detroit, USA.
73. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., et al. (2012) Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Engl J Med 366: 1382-1392.
74. Leitao Jr., M.M., Boyd, J., Hummer, A., Olvera, N., Arroyo, C.D., Venkatraman, E., et al. (2004) Clinicopathologic analysis of earlystage sporadic ovarian carcinoma. Am J Surg Pathol 28: 147-159.
75. Lengauer, C., Kinzler, K.W., and Vogelstein, B. (1997) Genetic instability in colorectal cancers. Nature 386: 623-627.
76. Levy-Lahad, E., Lahad, A., Eisenberg, S., Dagan, E., Paperna, T., Kasinetz, L., et al. (2001) A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98: 3232-3236.
77. Levy, S.F., Ziv, N., and Siegal, M.L. (2012) Bet hedging in yeast by heterogeneous, age-correlated expression of a stress protectant. PLoS Biol 10:e1001325.
78. Lupski, J.R. (2007) Genomic rearrangements and sporadic disease. Nat Genet 39:S43-47.
79. Maley, C.C., Galipeau, P.C., Finley, J.C., Wongsurawat, V.J., Li, X., Sanchez, C.A., et al. (2006) Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38: 468-473.
80. Meden, H., and Fattahi-Meibodi, A. (1998) CA 125 in benign gynecological conditions. Int J Biol Markers 13: 231-237.
81. Merlo, L.M., Pepper, J.W., Reid, B.J., and Maley, C.C. (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6: 924-935.
82. Moss, E.L., Hollingworth, J., and Reynolds, T.M. (2005) The role of CA125 in clinical practice. J Clin Pathol 58: 308-312.
83. Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472: 90-94.
84. Ng, C.K., Cooke, S.L., Howe, K., Newman, S., Xian, J., Temple, J., et al. (2012) The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. J Pathol 226: 703-712.
85. Nossov, V., Amneus, M., Su, F., Lang, J., Janco, J.M., Reddy, S.T., et al. (2008) The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 199: 215-223.
86. Nowell, P.C. (1976) The clonal evolution of tumor cell populations. Science 194: 23-28.
87. O'Huallachain, M., Karczewski, K.J., Weissman, S.M., Urban, A.E., and Snyder, M.P. (2012) Extensive genetic variation in somatic human tissues. Proc Natl Acad Sci USA 109: 18018-18023.
88. Olson, T.A., Mohanraj, D., Carson, L.F., and Ramakrishnan, S. (1994) Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54: 276-280.
89. Ozols, R.F. (2006) Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33:S3-11.
90. Paley, P.J., Staskus, K.A., Gebhard, K., Mohanraj, D., Twiggs, L.B., Carson, L.F., et al. (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80: 98-106.
91. Pavelka, N., Rancati, G., Zhu, J., Bradford, W.D., Saraf, A., Florens, L., et al. (2010) Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature 468: 321-325.
92. Pejovic, T., Himmelmann, A., Heim, S., Mandahl, N., Floderus, U.M., Furgyik, S., et al. (1992) Prognostic impact of chromosome aberrations in ovarian cancer. Br J Cancer 65: 282-286.
93. Pelkmans, L. (2012) Cell Biology. Using cell-to-cell variability-a new era in molecular biology. Science 336: 425-426.
94. Perren, T.J., Swart, A.M., Pfisterer, J., Ledermann, J.A., Pujade-Lauraine, E., Kristensen, G., et al. (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484-2496.
95. Pfisterer, J., Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., et al. (2006) Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98: 1036-1045.
96. Pieretti, M., Hopenhayn-Rich, C., Khattar, N.H., Cao, Y., Huang, B., and Tucker, T.C. (2002) Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 20: 11-23.
97. Rajagopalan, H., Nowak, M.A., Vogelstein, B., and Lengauer, C. (2003) The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 3: 695-701.
98. Ranpura, V., Hapani, S., and Wu, S. (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305: 487-494.
99. Rao, P.H., Harris, C.P., Yan Lu, X., Li, X.N., Mok, S.C., and Lau, C.C. (2002) Multicolor spectral karyotyping of serous ovarian adenocarcinoma. Genes Chromosomes Cancer 33: 123-132.
100. Roberts, N.J., Vogelstein, J.T., Parmigiani, G., Kinzler, K.W., Vogelstein, B., and Velculescu, V.E. (2012) The predictive capacity of personal genome sequencing. Sci Transl Med 4:133ra158.
101. Roberts, P.C., Mottillo, E.P., Baxa, A.C., Heng, H.H., Doyon-Reale, N., Gregoire, L., et al. (2005) Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model. Neoplasia 7: 944-956.
102. Roby, K.F., Taylor, C.C., Sweetwood, J.P., Cheng, Y., Pace, J.L., Tawfik, O., et al. (2000) Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21: 585-591.
103. Salvador, S., Rempel, A., Soslow, R.A., Gilks, B., Huntsman, D., and Miller, D. (2008) Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol 110: 408-417.
104. Shen, G.H., Ghazizadeh, M., Kawanami, O., Shimizu, H., Jin, E., Araki, T., et al. (2000) Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83: 196-203.
105. Shih, I.M., Zhou, W., Goodman, S.N., Lengauer, C., Kinzler, K.W., and Vogelstein, B. (2001) Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res 61: 818-822.
106. Sieben, N.L., Macropoulos, P., Roemen, G.M., Kolkman-Uljee, S.M., Jan Fleuren, G., Houmadi, R., et al. (2004) In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202: 336-340.
107. Siegel, R., Naishadham, D., and Jemal, A. (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
108. Silva, A.S., Kam, Y., Khin, Z.P., Minton, S.E., Gillies, R.J., and Gatenby, R.A. (2012) Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res 72: 6362-6370.
109. Sood, A.K., Sorosky, J.I., Dolan, M., Anderson, B., and Buller, R.E. (1999) Distant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res 5: 2485-2490.
110. Soslow, R.A. (2008) Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 27: 161-174.
111. Spannuth, W.A., Sood, A.K., and Coleman, R.L. (2008) Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 5: 194-204.
112. Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J., et al. (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144: 27-40.
113. Stevens, J.B., Liu, G., Bremer, S.W., Ye, K.J., Xu, W., Xu, J., et al. (2007) Mitotic cell death by chromosome fragmentation. Cancer Res 67: 7686-7694.
114. Stevens, J.B., Abdallah, B.Y., Regan, S.M., Liu, G., Bremer, S.W., Ye, C.J., et al. (2010) Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation. Mol Cytogenet 3:e1-e11.
115. Stevens, J.B., Abdallah, B.Y., Liu, G., Ye, C.J., Horne, S.D., Wang, G., et al. (2011) Diverse system stresses: common mechanisms of chromosome fragmentation. Cell Death Dis 2:e178-e186.
116. Stevens, J.B., Abdallah, B.Y., Liu, G, Horne, S.D., Bremer, S.W., Ye, K.J., et al. (2013a) Heterogeneity of cell death. Cytogenet Genome Res 139: 164-173.
117. Stevens, J.B., Horne, S.D., Abdallah, B.Y., Ye, C.J., and Heng, H.H. (2013b) Chromosomal instability and transcriptome dynamics in cancer. Cancer Metastasis Rev, in press.
118. TCGA. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
119. Tharapel, S.A., Qumsiyeh, M.B., and Photopulos, G. (1991) Numerical chromosome abnormalities associated with early clinical stages of gynecologic tumors. Cancer Genet Cytogenet 55: 89-96.
120. Tothill, R.W., Tinker, A.V., George, J., Brown, R., Fox, S.B., Lade, S., et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
121. Van Gorp, T., Cadron, I., Despierre, E., Daemen, A., Leunen, K., Amant, F., et al. (2011) HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 104: 863-870.
122. Venet, D., Dumont, J.E., and Detours, V. (2011) Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7:e1002240.
123. Vereczkey, I., Serester, O., Dobos, J., Gallai, M., Szakacs, O., Szentirmay, Z., et al. (2011) Molecular characterization of 103 ovarian serous and mucinous tumors. Pathol Oncol Res 17: 551-559.
124. Verhaak, R.G., Tamayo, P., Yang, J.Y., Hubbard, D., Zhang, H., Creighton, C.J., et al. (2013) Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123: 517-525.
125. Watson, J. (2013) Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 3:120144.
126. Welsh, J.B., Zarrinkar, P.P., Sapinoso, L.M., Kern, S.G., Behling, C.A., Monk, B.J., et al. (2001) Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98: 1176-1181.
127. Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjoblom, T., Leary, R.J., et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
128. Yates, L.R., and Campbell, P.J. (2012) Evolution of the cancer genome. Nat Rev Genet 13: 795-806.
129. Ye, C.J., Liu, G, Bremer, S.W., Heng, H.H. (2007) The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res 118: 237-246.
130. Ye, C.J., Stevens, J.B., Liu, G., Bremer, S.W., Jaiswal, A.S., Ye, K.J., et al. (2009) Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol 219: 288-300.
131. Yoshihara, K., Tajima, A., Yahata, T., Kodama, S., Fujiwara, H., Suzuki, M., et al. (2010) Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One 5:e9615.
132. Yousef, G.M., Polymeris, M.E., Yacoub, G.M., Scorilas, A., Soosaipillai, A., Popalis, C., et al. (2003) Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 63: 2223-2227.